Nektar Total Assets from 2010 to 2024

NKTR Stock

USD 1.42 0.02 1.43%

Nektar Therapeutics Total Assets yearly trend continues to be relatively stable with very little volatility. Total Assets are likely to grow to about 707.3 M this year. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

1994-03-31

Previous Quarter

398 M

Current Value

396 M

Quarterly Volatility

511.6 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Nektar Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nektar Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.4 M, Interest Expense of 23.9 M or Total Revenue of 162.3 M, as well as many indicators such as Price To Sales Ratio of 1.13, Dividend Yield of 0.0 or PTB Ratio of 0.78. Nektar financial statements analysis is a perfect complement when working with Nektar Therapeutics Valuation or Volatility modules.

Check out the analysis of Nektar Therapeutics Correlation against competitors.

To learn how to invest in Nektar Stock, please use our How to Invest in Nektar Therapeutics guide.

Latest Nektar Therapeutics' Total Assets Growth Pattern

Below is the plot of the Total Assets of Nektar Therapeutics over the last few years. Total assets refers to the total amount of Nektar Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Nektar Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Nektar Therapeutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Nektar Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 398.03 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Nektar Total Assets Regression Statistics

	Arithmetic Mean	811,792,575
	Geometric Mean	568,929,615
	Coefficient Of Variation	75.52
	Mean Deviation	471,508,493
	Median	568,871,000
	Standard Deviation	613,076,542
	Sample Variance	375862.8T
	Range	2.1B
	R-Value	0.40
	Mean Square Error	341323.5T
	R-Squared	0.16
	Significance	0.14
	Slope	54,276,873
	Total Sum of Squares	5262079.9T

Nektar Total Assets History

	2024	707.3 M
	2023	398 M
	2022	710.6 M
	2021	1.1 B
	2020	1.5 B
	2019	2 B
	2018	2.2 B

Other Fundumenentals of Nektar Therapeutics

Intangibles To Total Assets

Nektar Therapeutics Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Current Deferred Revenue	Short Term Investments	Common Stock	Net Receivables	Long Term Debt	Property Plant Equipment	Good Will	Intangible Assets	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.97	-0.01	-0.09	0.62	0.49	0.99	0.45	-0.29	0.99	-0.36	0.91	0.21	-0.15	-0.02	-0.65	0.94	0.46	0.55	-0.57	0.73	0.45	0.94	0.96	-0.09
Total Stockholder Equity	0.97		-0.11	0.0	0.59	0.29	0.97	0.41	-0.36	0.97	-0.18	0.91	0.31	-0.09	0.08	-0.57	0.98	0.4	0.58	-0.53	0.8	0.43	0.97	0.99	-0.07
Net Debt	-0.01	-0.11		-0.21	-0.1	0.41	-0.03	0.54	0.21	0.01	-0.41	-0.11	-0.23	-0.17	-0.37	-0.14	-0.11	0.2	-0.03	-0.12	-0.12	0.22	-0.09	-0.22	0.03
Retained Earnings	-0.09	0.0	-0.21		-0.46	-0.27	-0.14	0.16	0.53	-0.13	0.64	0.06	-0.05	-0.11	0.8	0.8	-0.08	-0.68	-0.69	0.73	0.45	-0.67	0.2	0.02	-0.8
Accounts Payable	0.62	0.59	-0.1	-0.46		0.35	0.68	0.28	-0.61	0.67	-0.32	0.53	0.23	-0.04	-0.22	-0.69	0.6	0.5	0.71	-0.63	0.07	0.48	0.47	0.61	0.31
Total Liab	0.49	0.29	0.41	-0.27	0.35		0.47	0.35	0.31	0.43	-0.84	0.44	-0.32	-0.31	-0.18	-0.5	0.19	0.43	0.05	-0.28	0.06	0.2	0.33	0.29	-0.27
Total Current Assets	0.99	0.97	-0.03	-0.14	0.68	0.47		0.39	-0.37	0.99	-0.34	0.92	0.29	-0.13	-0.03	-0.68	0.95	0.53	0.62	-0.62	0.68	0.51	0.93	0.96	-0.04
Short Term Debt	0.45	0.41	0.54	0.16	0.28	0.35	0.39		0.05	0.43	-0.18	0.27	-0.38	-0.16	0.03	-0.18	0.38	-0.2	0.02	0.07	0.4	-0.1	0.43	0.32	-0.23
Current Deferred Revenue	-0.29	-0.36	0.21	0.53	-0.61	0.31	-0.37	0.05		-0.4	-0.13	-0.23	-0.56	-0.41	0.33	0.53	-0.49	-0.4	-0.8	0.63	0.04	-0.62	-0.15	-0.35	-0.71
Short Term Investments	0.99	0.97	0.01	-0.13	0.67	0.43	0.99	0.43	-0.4		-0.29	0.9	0.32	-0.07	-0.02	-0.65	0.95	0.51	0.62	-0.62	0.68	0.51	0.93	0.96	-0.03
Common Stock	-0.36	-0.18	-0.41	0.64	-0.32	-0.84	-0.34	-0.18	-0.13	-0.29		-0.23	0.41	0.28	0.54	0.72	-0.13	-0.56	-0.3	0.45	0.1	-0.37	-0.12	-0.16	-0.16
Net Receivables	0.91	0.91	-0.11	0.06	0.53	0.44	0.92	0.27	-0.23	0.9	-0.23		0.36	-0.11	0.17	-0.46	0.85	0.48	0.45	-0.46	0.69	0.46	0.9	0.92	-0.22
Long Term Debt	0.21	0.31	-0.23	-0.05	0.23	-0.32	0.29	-0.38	-0.56	0.32	0.41	0.36		0.17	0.16	-0.05	0.35	0.5	0.45	-0.52	0.14	0.6	0.28	0.34	0.17
Property Plant Equipment	-0.15	-0.09	-0.17	-0.11	-0.04	-0.31	-0.13	-0.16	-0.41	-0.07	0.28	-0.11	0.17		0.14	0.02	-0.07	-0.12	0.19	0.04	-0.24	-0.03	-0.18	-0.07	0.29
Good Will	-0.02	0.08	-0.37	0.8	-0.22	-0.18	-0.03	0.03	0.33	-0.02	0.54	0.17	0.16	0.14		0.65	-0.06	-0.44	-0.45	0.5	0.27	-0.49	0.23	0.13	-0.79
Intangible Assets	-0.65	-0.57	-0.14	0.8	-0.69	-0.5	-0.68	-0.18	0.53	-0.65	0.72	-0.46	-0.05	0.02	0.65		-0.6	-0.73	-0.82	0.82	-0.12	-0.7	-0.4	-0.54	-0.56
Net Tangible Assets	0.94	0.98	-0.11	-0.08	0.6	0.19	0.95	0.38	-0.49	0.95	-0.13	0.85	0.35	-0.07	-0.06	-0.6		0.41	0.65	-0.58	0.78	0.48	0.92	0.96	0.08
Long Term Debt Total	0.46	0.4	0.2	-0.68	0.5	0.43	0.53	-0.2	-0.4	0.51	-0.56	0.48	0.5	-0.12	-0.44	-0.73	0.41		0.74	-0.89	-0.01	0.9	0.31	0.41	0.41
Capital Surpluse	0.55	0.58	-0.03	-0.69	0.71	0.05	0.62	0.02	-0.8	0.62	-0.3	0.45	0.45	0.19	-0.45	-0.82	0.65	0.74		-0.85	0.13	0.8	0.4	0.57	0.69
Deferred Long Term Liab	-0.57	-0.53	-0.12	0.73	-0.63	-0.28	-0.62	0.07	0.63	-0.62	0.45	-0.46	-0.52	0.04	0.5	0.82	-0.58	-0.89	-0.85		-0.09	-0.91	-0.38	-0.52	-0.53
Long Term Investments	0.73	0.8	-0.12	0.45	0.07	0.06	0.68	0.4	0.04	0.68	0.1	0.69	0.14	-0.24	0.27	-0.12	0.78	-0.01	0.13	-0.09		0.06	0.87	0.78	-0.35
Short Long Term Debt	0.45	0.43	0.22	-0.67	0.48	0.2	0.51	-0.1	-0.62	0.51	-0.37	0.46	0.6	-0.03	-0.49	-0.7	0.48	0.9	0.8	-0.91	0.06		0.28	0.4	0.54
Net Invested Capital	0.94	0.97	-0.09	0.2	0.47	0.33	0.93	0.43	-0.15	0.93	-0.12	0.9	0.28	-0.18	0.23	-0.4	0.92	0.31	0.4	-0.38	0.87	0.28		0.96	-0.28
Net Working Capital	0.96	0.99	-0.22	0.02	0.61	0.29	0.96	0.32	-0.35	0.96	-0.16	0.92	0.34	-0.07	0.13	-0.54	0.96	0.41	0.57	-0.52	0.78	0.4	0.96		-0.1
Capital Stock	-0.09	-0.07	0.03	-0.8	0.31	-0.27	-0.04	-0.23	-0.71	-0.03	-0.16	-0.22	0.17	0.29	-0.79	-0.56	0.08	0.41	0.69	-0.53	-0.35	0.54	-0.28	-0.1

Click cells to compare fundamentals

About Nektar Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Nektar Therapeutics income statement, its balance sheet, and the statement of cash flows. Nektar Therapeutics investors use historical funamental indicators, such as Nektar Therapeutics's Total Assets, to determine how well the company is positioned to perform in the future. Although Nektar Therapeutics investors may use each financial statement separately, they are all related. The changes in Nektar Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Nektar Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Nektar Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Nektar Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Total Assets	398 M	707.3 M
Intangibles To Total Assets	0.12	0.15

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Additional Tools for Nektar Stock Analysis

When running Nektar Therapeutics' price analysis, check to measure Nektar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nektar Therapeutics is operating at the current time. Most of Nektar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nektar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nektar Therapeutics' price. Additionally, you may evaluate how the addition of Nektar Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC